|
1941 |
Hydralazine
Enthalten in Reactions weekly Bd. 1677, 11.11.2017, Nr. 1, date:11.2017: 150
|
|
|
|
1942 |
Hydralazine
Enthalten in Reactions weekly Bd. 1652, 20.5.2017, Nr. 1, date:5.2017: 149
|
|
|
|
1943 |
Hydroxycarbamide
Enthalten in Reactions weekly Bd. 1653, 27.5.2017, Nr. 1, date:5.2017: 158
|
|
|
|
1944 |
Hydroxychloroquine
Enthalten in Reactions weekly Bd. 1662, 29.7.2017, Nr. 1, date:7.2017: 196
|
|
|
|
1945 |
Hydroxychloroquine
Enthalten in Reactions weekly Bd. 1663, 5.8.2017, Nr. 1, date:8.2017: 142
|
|
|
|
1946 |
Hydroxychloroquine
Enthalten in Reactions weekly Bd. 1643, 18.3.2017, Nr. 1, date:3.2017: 148
|
|
|
|
1947 |
Hydroxychloroquine inhibits CD154 expression in CD4+ T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling
Enthalten in Arthritis Research & Therapy Bd. 19, 9.8.2017, Nr. 1, date:12.2017: 1-14
|
|
|
|
1948 |
Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review
Enthalten in Clinical rheumatology Bd. 36, 9.5.2017, Nr. 8, date:8.2017: 1919-1926
|
|
|
|
1949 |
ICER draft report assesses three osteoporosis therapies
Enthalten in PharmacoEconomics & outcomes news Bd. 778, 20.5.2017, Nr. 1, date:5.2017: 2
|
|
|
|
1950 |
ICER issues draft report on non-drug neck/back pain treatments
Enthalten in PharmacoEconomics & outcomes news Bd. 776, 22.4.2017, Nr. 1, date:4.2017: 1
|
|
Administration
